IDH2 and glioblastoma: Glioblastomas CNS WHO 4 are currently defined by the absence of IDH and H3 mutations and occurrence of at least one of the following histopathological (microvascular proliferations, necrosis) or molecular (chromosome +7/−10 signature, EGFR amplification, TERT promoter mutation) alterations.